logo BDSP

Base documentaire

  1. Breast conserving surgery for invasive breast cancer : Risk factors for ipsilateral breast tumor recurrences.

    Article - En anglais

    To identify risk factors associated with an increased risk for ipsilateral breast tumor recurrence following breast-conserving surgery, a cohort of 759 women with T1-T2 tumors were studied.

    The majority of the patients (88%) had received postoperative radiation therapy to the breast.

    Median follow-up time was 10 (range : 6-17) years.

    There was a 1-1.5% yearly increase in ipsilateral breast tumor recurrences.

    For women<50 ys the cumulative recurrence rate at 10 years was 18% and for women = 50 ys, 9%. Node positive women had a cumulative breast recurrence rate of 25% versus 10% for node negative women.

    Ten years postoperatively, irradiated patients had a cumulative recurrence rate of 11% versus 26% when no irradiation was given.

    The beneficial effect of radiotherapy was substantial during the first four postoperative years.

    The relative risk for an ipsilateral breast tumor recurrence during this period was 4.5 times higher than for non irradiated patients.

    However, the protective effect of radiotherapy decreased with time.

    After ten years the relative risk of ipsilateral breast tumor recurrence was the same among irradiated and non-irradiated patients although the number of events during this period was low. (...)

    Mots-clés Pascal : Chirurgie conservatrice, Traitement adjuvant, Radiothérapie, Tumeur maligne, Glande mammaire, Potentiel, Métastatique, Homme, Facteur risque, Récidive, Ipsilatéral, Epidémiologie, Suède, Europe, Antioestrogène, Antihormone, Composé non stéroïde, Chimiothérapie, Glande mammaire pathologie, Femelle, Tamoxifène, Anticancéreux

    Mots-clés Pascal anglais : Conservative surgery, Adjuvant treatment, Radiotherapy, Malignant tumor, Mammary gland, Potential, Metastatic, Human, Risk factor, Relapse, Ipsilateral, Epidemiology, Sweden, Europe, Antiestrogen, Antihormone, Non steroid compound, Chemotherapy, Mammary gland diseases, Female, Tamoxifene, Antineoplastic agent

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0226829

    Code Inist : 002B20E02. Création : 11/06/1997.